Annual Net Income
-$111.40 M
+$167.08 M+60.00%
December 31, 2023
Summary
- As of February 7, 2025, TVTX annual net profit is -$111.40 million, with the most recent change of +$167.08 million (+60.00%) on December 31, 2023.
- During the last 3 years, TVTX annual net income has risen by +$58.03 million (+34.25%).
- TVTX annual net income is now -195.02% below its all-time high of $117.24 million, reached on December 31, 2015.
Performance
TVTX Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Net Income
-$54.81 M
+$15.60 M+22.15%
September 30, 2024
Summary
- As of February 7, 2025, TVTX quarterly net profit is -$54.81 million, with the most recent change of +$15.60 million (+22.15%) on September 30, 2024.
- Over the past year, TVTX quarterly net income has increased by +$35.36 million (+39.22%).
- TVTX quarterly net income is now -136.36% below its all-time high of $150.74 million, reached on September 30, 2023.
Performance
TVTX Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM Net Income
-$351.45 M
-$205.55 M-140.87%
September 30, 2024
Summary
- As of February 7, 2025, TVTX TTM net profit is -$351.45 million, with the most recent change of -$205.55 million (-140.87%) on September 30, 2024.
- Over the past year, TVTX TTM net income has dropped by -$240.06 million (-215.49%).
- TVTX TTM net income is now -399.78% below its all-time high of $117.24 million, reached on December 31, 2015.
Performance
TVTX TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Net Income Formula
Net Income = Revenue − COGS − Operating Expenses − Interest − Taxes − Other Expenses
TVTX Net Income Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +60.0% | +39.2% | -215.5% |
| 3 y3 years | +34.3% | +16.7% | -26.2% |
| 5 y5 years | -8.5% | +16.7% | -26.2% |
TVTX Net Income Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +60.0% | -136.4% | +59.7% | -303.7% | at low |
| 5 y | 5-year | at high | +60.0% | -136.4% | +59.7% | -350.2% | at low |
| alltime | all time | -195.0% | +60.0% | -136.4% | +59.7% | -399.8% | at low |
Travere Therapeutics Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$54.81 M(-22.2%) | -$351.45 M(+140.9%) |
| Jun 2024 | - | -$70.41 M(-48.3%) | -$145.91 M(-9.4%) |
| Mar 2024 | - | -$136.06 M(+50.9%) | -$161.13 M(+44.6%) |
| Dec 2023 | -$111.40 M(-60.0%) | -$90.17 M(-159.8%) | -$111.40 M(+28.0%) |
| Sep 2023 | - | $150.74 M(-276.0%) | -$87.05 M(-71.7%) |
| Jun 2023 | - | -$85.63 M(-0.8%) | -$307.44 M(+6.4%) |
| Mar 2023 | - | -$86.33 M(+31.2%) | -$288.84 M(+3.7%) |
| Dec 2022 | -$278.48 M(+54.6%) | -$65.82 M(-5.5%) | -$278.48 M(+5.4%) |
| Sep 2022 | - | -$69.66 M(+3.9%) | -$264.23 M(+14.8%) |
| Jun 2022 | - | -$67.03 M(-11.8%) | -$230.22 M(+13.9%) |
| Mar 2022 | - | -$75.97 M(+47.3%) | -$202.19 M(+12.3%) |
| Dec 2021 | -$180.09 M(+6.3%) | -$51.57 M(+44.7%) | -$180.09 M(-28.0%) |
| Sep 2021 | - | -$35.64 M(-8.6%) | -$250.14 M(+5.5%) |
| Jun 2021 | - | -$39.01 M(-27.6%) | -$237.05 M(+5.8%) |
| Mar 2021 | - | -$53.87 M(-55.7%) | -$224.11 M(+32.3%) |
| Dec 2020 | -$169.43 M(+15.7%) | -$121.62 M(+439.4%) | -$169.43 M(+117.0%) |
| Sep 2020 | - | -$22.55 M(-13.5%) | -$78.07 M(-15.2%) |
| Jun 2020 | - | -$26.07 M(-3326.2%) | -$92.01 M(-12.1%) |
| Mar 2020 | - | $808.00 K(-102.7%) | -$104.64 M(-28.5%) |
| Dec 2019 | -$146.43 M(+42.6%) | -$30.26 M(-17.1%) | -$146.43 M(+18.4%) |
| Sep 2019 | - | -$36.49 M(-5.7%) | -$123.62 M(-12.7%) |
| Jun 2019 | - | -$38.70 M(-5.6%) | -$141.65 M(+13.1%) |
| Mar 2019 | - | -$40.98 M(+449.7%) | -$125.28 M(+22.0%) |
| Dec 2018 | -$102.68 M(+71.9%) | -$7.46 M(-86.3%) | -$102.68 M(-9.0%) |
| Sep 2018 | - | -$54.52 M(+144.1%) | -$112.84 M(+48.2%) |
| Jun 2018 | - | -$22.33 M(+21.5%) | -$76.12 M(+13.6%) |
| Mar 2018 | - | -$18.38 M(+4.3%) | -$67.02 M(+12.2%) |
| Dec 2017 | -$59.73 M | -$17.62 M(-1.0%) | -$59.73 M(+17.8%) |
| Sep 2017 | - | -$17.79 M(+34.5%) | -$50.72 M(-27.6%) |
| Jun 2017 | - | -$13.23 M(+19.3%) | -$70.03 M(-0.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2017 | - | -$11.09 M(+28.9%) | -$70.21 M(+46.6%) |
| Dec 2016 | -$47.90 M(-140.9%) | -$8.60 M(-76.8%) | -$47.90 M(+14.7%) |
| Sep 2016 | - | -$37.11 M(+176.9%) | -$41.77 M(-141.4%) |
| Jun 2016 | - | -$13.40 M(-219.5%) | $100.92 M(+13.7%) |
| Mar 2016 | - | $11.22 M(-554.3%) | $88.80 M(-24.3%) |
| Dec 2015 | $117.24 M(-205.7%) | -$2.47 M(-102.3%) | $117.24 M(+29.3%) |
| Sep 2015 | - | $105.58 M(-513.6%) | $90.68 M(-375.8%) |
| Jun 2015 | - | -$25.53 M(-164.4%) | -$32.88 M(-838.4%) |
| Mar 2015 | - | $39.66 M(-236.6%) | $4.45 M(-104.0%) |
| Dec 2014 | -$110.94 M(+220.4%) | -$29.03 M(+61.4%) | -$110.94 M(+15.7%) |
| Sep 2014 | - | -$17.98 M(-252.3%) | -$95.85 M(+8.0%) |
| Jun 2014 | - | $11.80 M(-115.6%) | -$88.76 M(-16.0%) |
| Mar 2014 | - | -$75.74 M(+443.5%) | -$105.62 M(+203.9%) |
| Dec 2013 | -$34.63 M(+14.1%) | -$13.94 M(+27.9%) | -$34.75 M(+66.9%) |
| Sep 2013 | - | -$10.90 M(+115.9%) | -$20.82 M(+109.8%) |
| Jun 2013 | - | -$5.05 M(+3.7%) | -$9.92 M(+103.4%) |
| Mar 2013 | - | -$4.87 M(>+9900.0%) | -$4.88 M(>+9900.0%) |
| Dec 2012 | -$30.34 M(>+9900.0%) | - | - |
| Nov 2012 | - | -$3700.00(+5.7%) | -$15.00 K(+1.4%) |
| Aug 2012 | - | -$3500.00(0.0%) | -$14.80 K(0.0%) |
| May 2012 | - | -$3500.00(-18.6%) | -$14.80 K(0.0%) |
| Feb 2012 | - | -$4300.00(+22.9%) | -$14.80 K(+1.4%) |
| Feb 2012 | -$14.80 K(-35.7%) | - | - |
| Nov 2011 | - | -$3500.00(0.0%) | -$14.60 K(-13.1%) |
| Aug 2011 | - | -$3500.00(0.0%) | -$16.80 K(-15.6%) |
| May 2011 | - | -$3500.00(-14.6%) | -$19.90 K(-13.5%) |
| Feb 2011 | -$23.00 K | -$4100.00(-28.1%) | -$23.00 K(+21.7%) |
| Nov 2010 | - | -$5700.00(-13.6%) | -$18.90 K(+43.2%) |
| Aug 2010 | - | -$6600.00(0.0%) | -$13.20 K(+100.0%) |
| May 2010 | - | -$6600.00 | -$6600.00 |
FAQ
- What is Travere Therapeutics annual net profit?
- What is the all time high annual net income for Travere Therapeutics?
- What is Travere Therapeutics annual net income year-on-year change?
- What is Travere Therapeutics quarterly net profit?
- What is the all time high quarterly net income for Travere Therapeutics?
- What is Travere Therapeutics quarterly net income year-on-year change?
- What is Travere Therapeutics TTM net profit?
- What is the all time high TTM net income for Travere Therapeutics?
- What is Travere Therapeutics TTM net income year-on-year change?
What is Travere Therapeutics annual net profit?
The current annual net income of TVTX is -$111.40 M
What is the all time high annual net income for Travere Therapeutics?
Travere Therapeutics all-time high annual net profit is $117.24 M
What is Travere Therapeutics annual net income year-on-year change?
Over the past year, TVTX annual net profit has changed by +$167.08 M (+60.00%)
What is Travere Therapeutics quarterly net profit?
The current quarterly net income of TVTX is -$54.81 M
What is the all time high quarterly net income for Travere Therapeutics?
Travere Therapeutics all-time high quarterly net profit is $150.74 M
What is Travere Therapeutics quarterly net income year-on-year change?
Over the past year, TVTX quarterly net profit has changed by +$35.36 M (+39.22%)
What is Travere Therapeutics TTM net profit?
The current TTM net income of TVTX is -$351.45 M
What is the all time high TTM net income for Travere Therapeutics?
Travere Therapeutics all-time high TTM net profit is $117.24 M
What is Travere Therapeutics TTM net income year-on-year change?
Over the past year, TVTX TTM net profit has changed by -$240.06 M (-215.49%)